<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002768</url>
  </required_header>
  <id_info>
    <org_study_id>CALGB-9620</org_study_id>
    <secondary_id>U10CA031946</secondary_id>
    <secondary_id>CLB-9620</secondary_id>
    <secondary_id>CDR0000064734</secondary_id>
    <nct_id>NCT00002768</nct_id>
  </id_info>
  <brief_title>Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Acute Myeloid Leukemia in Second Remission</brief_title>
  <official_title>AUTOLOGOUS STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA IN SECOND REMISSION: A PHASE II STUDY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alliance for Clinical Trials in Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Alliance for Clinical Trials in Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation&#xD;
      may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell transplantation&#xD;
      following chemotherapy in treating patients with acute myeloid leukemia in second remission.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the ability of mobilization using cytarabine, etoposide, and&#xD;
      filgrastim (G-CSF), conditioning using busulfan and etoposide, and autologous peripheral&#xD;
      blood stem cell transplantation to generate a 2-year disease-free survival rate in at least&#xD;
      30% of patients with acute myeloid leukemia (AML) in second complete remission. II. Determine&#xD;
      whether the treatment-related mortality can be limited to less than 20% in patients treated&#xD;
      with this regimen. III. Determine whether adequate numbers of PBSC can be collected in these&#xD;
      patients. IV. Determine the engraftment kinetics of primed PBSC obtained from these patients.&#xD;
&#xD;
      OUTLINE: Mobilization/harvest: Patients receive cytarabine IV over 2 hours every 12 hours and&#xD;
      etoposide IV continuously on days 1-4. Filgrastim (G-CSF) is administered subcutaneously (SC)&#xD;
      beginning on day 14 and continuing until peripheral blood stem cells (PBSC) are harvested.&#xD;
      When blood counts recover, PBSC are harvested and selected for CD34+ cells. Conditioning:&#xD;
      Beginning at least 4 weeks after hospital discharge for mobilization and harvest and when&#xD;
      blood counts recover, patients receive oral busulfan every 6 hours on days -7 to -4 and&#xD;
      etoposide IV over 4 hours on day -3. PBSC are reinfused on day 0. G-CSF is administered SC&#xD;
      beginning on day 0 and continuing until blood counts recover. Patients with documented CNS&#xD;
      disease at first relapse receive methotrexate intrathecally at intervals of 1 week or greater&#xD;
      before and/or after PBSC transplantation for a total of 6 doses. Patients are followed every&#xD;
      3 months for 2 years and then every 6 months for 3 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 26-48 patients will be accrued within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 1996</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">February 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Autologous stem cell transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive consolidation chemotherapy followed by autologous stem cell transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>10 microgram/kg body wt subcutaneously daily beginning on d 14 and con't until peripheral blood collection is completed</description>
    <arm_group_label>Autologous stem cell transplantation</arm_group_label>
    <other_name>G-CSF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
    <description>1 mg/kg PO q 6 hrs for 16 doses on days -7 thru -4.</description>
    <arm_group_label>Autologous stem cell transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <description>2000 mg/ sq meter IV over 2 hours q 12 hrs x 8 doses on days 1-4</description>
    <arm_group_label>Autologous stem cell transplantation</arm_group_label>
    <other_name>Ara-C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <description>40 mg/kg (total dose) IV cont infusion over 96 hrs on days 1-4 of consolidation therapy and 60 mg/kg IV over 4 hrs on day -3 of transplant</description>
    <arm_group_label>Autologous stem cell transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>For patients with documented CNS disease at first relapse, 12 mg intrathecal for a total of 6 doses given before and/or after transplantation</description>
    <arm_group_label>Autologous stem cell transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <description>Infusion on Day 0</description>
    <arm_group_label>Autologous stem cell transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Diagnosis of acute myeloid leukemia (AML) in second complete&#xD;
        remission (CR) for 30 days to less than 1 year before study entry Second CR defined by the&#xD;
        following: Neutrophil count at least 1,000/mm3 Platelet count at least 100,000/mm3 Normal&#xD;
        bone marrow morphology with no excess blasts (greater than 5%) No myelodysplasia No&#xD;
        extramedullary or CNS leukemia Initial diagnosis of de novo AML (M0-M7) No prior&#xD;
        myelodysplasia No myeloproliferative disease No secondary AML Cytogenetics not required No&#xD;
        cytogenetic evidence of persistent leukemia if cytogenetics performed&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 15 to 69 Hematopoietic: See Disease Characteristics&#xD;
        Granulocyte count at least 1,000/mm3 Hepatic: Bilirubin less than 1.5 mg/dL AST less than 3&#xD;
        times normal Alkaline phosphatase less than 3 times normal No cirrhosis or chronic&#xD;
        hepatitis Biopsy required if chronic liver disease suspected (history of alcohol abuse or&#xD;
        possible hepatitis) Renal: Creatinine less than 2.0 mg/dL Other: Not pregnant or nursing&#xD;
        Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior bone marrow/stem cell transplantation&#xD;
        Chemotherapy: Prior non-ablative chemotherapy at initial diagnosis, during initial&#xD;
        remission, or as reinduction therapy (to produce current second remission) allowed At least&#xD;
        4 weeks since hospital discharge after reinduction therapy Endocrine therapy: Not specified&#xD;
        Radiotherapy: Not specified Surgery: Not specified Other: No prior post-remission therapy&#xD;
        for second remission&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Linker, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Cancer Center and Cancer Research Institute</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115-0128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marlene &amp; Stewart Greenebaum Cancer Center, University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital and Medical Center</name>
      <address>
        <city>Paterson</city>
        <state>New Jersey</state>
        <zip>07503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Linker CA, Owzar K, Powell B, Hurd D, Damon LE, Archer LE, Larson RA; Cancer and Leukemia Group B. Auto-SCT for AML in second remission: CALGB study 9620. Bone Marrow Transplant. 2009 Sep;44(6):353-9. doi: 10.1038/bmt.2009.36. Epub 2009 Mar 16.</citation>
    <PMID>19289999</PMID>
  </results_reference>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>April 21, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2004</study_first_posted>
  <last_update_submitted>June 27, 2016</last_update_submitted>
  <last_update_submitted_qc>June 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>adult acute erythroid leukemia (M6)</keyword>
  <keyword>adult acute myeloblastic leukemia without maturation (M1)</keyword>
  <keyword>adult acute myeloblastic leukemia with maturation (M2)</keyword>
  <keyword>adult acute promyelocytic leukemia (M3)</keyword>
  <keyword>adult acute myelomonocytic leukemia (M4)</keyword>
  <keyword>adult acute monoblastic leukemia (M5a)</keyword>
  <keyword>adult acute megakaryoblastic leukemia (M7)</keyword>
  <keyword>adult acute monocytic leukemia (M5b)</keyword>
  <keyword>adult acute minimally differentiated myeloid leukemia (M0)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

